Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.

Molecular cancer therapeutics - 1 Oct 2021

Fujihara Kenji M, Corrales Benitez Mariana, Cabalag Carlos S, Zhang Bonnie Z, Ko Hyun S, Liu David S, Simpson Kaylene J, Haupt Ygal, Lipton Lara, Haupt Sue, Phillips Wayne A, Clemons Nicholas J

Abstract excerpt

APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation is an inclusion criterion for patient selection into most APR-246 clinical trials. Preliminary results from our phase Ib/II clinical trial investigating APR-246 combined with doublet chemotherapy [cisplatin and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Fluorouracil

Share to Metabolome

Share to Proteome

Share to Transcriptome

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 34315763
DOI: 10.1158/1535-7163.MCT-21-0067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.PMID 34315763Read ↗

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation statusSemantic proximity Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read ↗

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.Semantic proximity Read ↗

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read ↗

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.Semantic proximity Read ↗

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies.Semantic proximity Read ↗

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read ↗

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.Semantic proximity Read ↗

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read ↗

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Semantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.